Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Class A Ordinary Shares, par value $0.0001 per share
-
Shares outstanding
-
63.5M
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
39.4M
-
Shares change
-
+1.67M
-
Total reported value, excl. options
-
$843M
-
Value change
-
+$59.3M
-
Number of buys
-
32
-
Number of sells
-
-17
-
Price
-
$21.39
Significant Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) as of Q1 2023
54 filings reported holding MLTX - MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share as of Q1 2023.
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.4M shares
of 63.5M outstanding shares and own 62.09% of the company stock.
Largest 10 shareholders include BVF INC/IL (21.8M shares), Cormorant Asset Management, LP (6.89M shares), CITADEL ADVISORS LLC (2.92M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.67M shares), Polar Capital Holdings Plc (876K shares), PRICE T ROWE ASSOCIATES INC /MD/ (831K shares), FEDERATED HERMES, INC. (804K shares), RTW INVESTMENTS, LP (500K shares), FMR LLC (475K shares), and JPMORGAN CHASE & CO (303K shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.